Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 8/20 | 0.79 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21496807 | 0.89 | HDAC11 (1.00) | HDAC11HDAC8HDAC6 | |
| SCHEMBL25932104 | 0.86 | HDAC11 (0.59) | HDAC11HDAC6 | |
| SCHEMBL21496747 | 0.82 | HDAC11 (0.59) | HDAC11HDAC8HDAC6 | |
| SCHEMBL21496730 | 0.81 | HDAC11 (0.81) | HDAC11HDAC8 | |
| SCHEMBL21496823 | 0.80 | HDAC11 (0.63) | HDAC11HDAC6 | |
| SCHEMBL25932254 | 0.77 | HDAC11 (0.53) | HDAC11HDAC6 | |
| SCHEMBL21496741 | 0.76 | HDAC11 (0.75) | HDAC11 | |
| SCHEMBL21496674 | 0.76 | HDAC11 (0.55) | HDAC11HDAC6 | |
| SCHEMBL25932103 | 0.75 | HDAC11 (0.76) | HDAC11HDAC8HDAC6 | |
| SCHEMBL21496820 | 0.72 | HDAC11 (0.49) | HDAC11HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-11535607-B2 | Isoindolines as HDAC inhibitors | VALO HEALTH, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3784654-A1 | ISOINDOLINES AS HDAC INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| WO-2019204550-A1 | ISOINDOLINES AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
| WO-2019204550-A1 | ISOINDOLINES AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535607-B2 | Isoindolines as HDAC inhibitors | HDAC1, HDAC2, HDAC3 | HDAC11 4/4885HDAC8 9/4885HDAC6 8/4885 |
| US-20230242512-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | HDAC11 4/4885HDAC8 9/4885HDAC6 8/4885 |
| US-20210253555-A1 | ISOINDOLINES AS HDAC INHIBITORS | HDAC1, HDAC2, HDAC3 | HDAC11 4/4885HDAC8 9/4885HDAC6 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.